目的:本研究主要探讨糖肾平对糖尿病肾病(DKD)KK-Ay小鼠肾脏保护作用及其对TGF-β_1/Samd6/BMP7信号通路的影响。方法:10只雌性C57BL/6J小鼠作为对照组。雌性10周龄KK-Ay小鼠60只,KK鼠料诱导10周后建立糖尿病肾病动物模型。模型小鼠按...目的:本研究主要探讨糖肾平对糖尿病肾病(DKD)KK-Ay小鼠肾脏保护作用及其对TGF-β_1/Samd6/BMP7信号通路的影响。方法:10只雌性C57BL/6J小鼠作为对照组。雌性10周龄KK-Ay小鼠60只,KK鼠料诱导10周后建立糖尿病肾病动物模型。模型小鼠按体质量和血糖区组分层随机法分为模型组、厄贝沙坦组与糖肾平小、中、大剂量组。厄贝沙坦组,糖肾平小、中、大剂量组均灌胃给药,正常组、模型组用等体积去离子水灌胃。每4周称体质量和测24 h尿蛋白定量。实验第26周,眼球取血并处死小鼠,称肾脏质量、测血糖,分离血清测BUN、Scr、TG、MDA、NO和SOD;HE染色和Mallory染色观察肾组织病理形态;原位杂交、免疫组化、Western blot检测肾组织TGF-β_1、Samd6、BMP7、α-SMA、E-Cadherin m RNA及蛋白表达。结果:与模型组比较,各治疗组体质量、肾质量/体质量、尿蛋白降低,其中糖肾平中、大剂量组有显著性差异(P<0.01);肾脏病理损害明显减轻,FBG、血清BUN、Scr、TG和MDA含量明显降低(P<0.01),NO、SOD含量明显增加(P<0.01),Samd6、BMP7和E-Cadherin m RNA及蛋白的表达量增加,TGF-β_1和α-SMA m RNA及蛋白的表达量减少,其中糖肾平大剂量组有显著性差异(P<0.01),糖肾平的治疗效果呈剂量依赖关系。结论:糖肾平对DKD KK-Ay小鼠肾脏保护及逆转肾小管上皮细胞转分化的作用,可能与下调氧化应激水平及调节TGF-β_1/Samd6/BMP7信号通路有关,这为DKD"肾痿"学说提供了新的实验依据。展开更多
Dietary intake of 0.1% fucoxanthin significantly reduced lipid hydroperoxide levels of liver and abdominal white adipose tissue (WAT) of obese/diabetes KK-Ay mice. The fucoxanthin supplementation also significantly re...Dietary intake of 0.1% fucoxanthin significantly reduced lipid hydroperoxide levels of liver and abdominal white adipose tissue (WAT) of obese/diabetes KK-Ay mice. The fucoxanthin supplementation also significantly reduced blood glucose level and hepatic lipid contents of the mice. Oxidative stress is known to be induced in hyperglycemia and high fat conditions. Therefore, in vivo antioxidant activity of fucoxanthin found in the present study could be attributed to its anti-diabetic effect and its decreasing effect on hepatic lipids. On the other hand, little effect of fucoxanthin on lipid hydroperoxide levels was found in normal ICR mice. Although the content of fucoxanthin metabolites in the abdominal WAT of KK-Ay mice was about 50 times higher that in the liver, there was little difference in its In Vivo antioxidant activity between in the liver and in the abdominal WAT. These results suggest that well-known ability of fucoxanthin to scavenge active oxygen species and/or free radicals would not be a main reason to explain its In Vivo antioxidant activity.展开更多
基金National Major Scientific and Technological Special Project for Signaficant New Drugs Development(No.2011ZX09101-004-04)Innovation Team Project of Beijing University of Chinese Medicine(No.2011CXTD-19)+1 种基金Ministry of Education Key Laboratory of Health Preservation of Chinese MedicineBeijing Key Laboratory of Health Preservation of Chinese Medicine~~
文摘目的:本研究主要探讨糖肾平对糖尿病肾病(DKD)KK-Ay小鼠肾脏保护作用及其对TGF-β_1/Samd6/BMP7信号通路的影响。方法:10只雌性C57BL/6J小鼠作为对照组。雌性10周龄KK-Ay小鼠60只,KK鼠料诱导10周后建立糖尿病肾病动物模型。模型小鼠按体质量和血糖区组分层随机法分为模型组、厄贝沙坦组与糖肾平小、中、大剂量组。厄贝沙坦组,糖肾平小、中、大剂量组均灌胃给药,正常组、模型组用等体积去离子水灌胃。每4周称体质量和测24 h尿蛋白定量。实验第26周,眼球取血并处死小鼠,称肾脏质量、测血糖,分离血清测BUN、Scr、TG、MDA、NO和SOD;HE染色和Mallory染色观察肾组织病理形态;原位杂交、免疫组化、Western blot检测肾组织TGF-β_1、Samd6、BMP7、α-SMA、E-Cadherin m RNA及蛋白表达。结果:与模型组比较,各治疗组体质量、肾质量/体质量、尿蛋白降低,其中糖肾平中、大剂量组有显著性差异(P<0.01);肾脏病理损害明显减轻,FBG、血清BUN、Scr、TG和MDA含量明显降低(P<0.01),NO、SOD含量明显增加(P<0.01),Samd6、BMP7和E-Cadherin m RNA及蛋白的表达量增加,TGF-β_1和α-SMA m RNA及蛋白的表达量减少,其中糖肾平大剂量组有显著性差异(P<0.01),糖肾平的治疗效果呈剂量依赖关系。结论:糖肾平对DKD KK-Ay小鼠肾脏保护及逆转肾小管上皮细胞转分化的作用,可能与下调氧化应激水平及调节TGF-β_1/Samd6/BMP7信号通路有关,这为DKD"肾痿"学说提供了新的实验依据。
文摘Dietary intake of 0.1% fucoxanthin significantly reduced lipid hydroperoxide levels of liver and abdominal white adipose tissue (WAT) of obese/diabetes KK-Ay mice. The fucoxanthin supplementation also significantly reduced blood glucose level and hepatic lipid contents of the mice. Oxidative stress is known to be induced in hyperglycemia and high fat conditions. Therefore, in vivo antioxidant activity of fucoxanthin found in the present study could be attributed to its anti-diabetic effect and its decreasing effect on hepatic lipids. On the other hand, little effect of fucoxanthin on lipid hydroperoxide levels was found in normal ICR mice. Although the content of fucoxanthin metabolites in the abdominal WAT of KK-Ay mice was about 50 times higher that in the liver, there was little difference in its In Vivo antioxidant activity between in the liver and in the abdominal WAT. These results suggest that well-known ability of fucoxanthin to scavenge active oxygen species and/or free radicals would not be a main reason to explain its In Vivo antioxidant activity.
